CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
CStone has successfully built up a world-class management team, with clinical development and translational medicine as its core competence. Combining with significant financial funding and rich oncology pipeline, CStone is uniquely positioned as the partner of choice for multi-national pharmaceutical / biotech companies to develop drugs in China and the Asia Pacific region.
Currently, CStone is seeking strategic partners in the following areas: